29/09/09

Scientists use nanotech to ‘upgrade’ TB drugs

Rifanano is coated with nanoparticles to enable easier absorption Copyright: Lawrence Berkeley National Laboratory

By: Carol Campbell

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Scientists use nanotech to ‘upgrade’ TB drugs</h1>
<h4>By: Carol Campbell</h4>
</div>
<br />
<br />

<div id="article-body">
<p><span>[DURBAN] South African scientists have used nanotechnology to enhance the absorption of tuberculosis (TB) drugs in the body so that fewer, smaller doses are needed.</span></p>
<p><span>Clinical trials for the antibiotic, Rifanano — a combination of the four main first-line TB drugs — are scheduled for 2012 and the drug should be available in government clinics in 2016, Hulda Swai, principal researcher in biomaterials research told SciDev.Net.</span></p>
<p><span>Swai and her team from the Council for Scientific and Industrial Research (CSIR) won ‘best science to business opportunity’ at the second SA Bio Plan Competition held during the recent Bio2Biz Conference in South Africa last week (20–23 September).</span></p>
<p><span>Rifanano needs to be taken just once a week for two months and there are no adverse reactions. Most TB antibiotics must be taken daily for up to six months and often cause debilitating side effects, such as nausea and fatigue.</span></p>
<p><span>The new drug is coated with nano-sized particles which are in turn coated with chemicals that make them stick to the intestine wall, enabling the drug to be far more easily absorbed. </span></p>
<p><span>"When the white blood cells see these particles they take them up because they look like foreign objects. But doing so they actually transport them throughout the body while releasing their cargo," says Swai.</span></p>
<p><span>"We have not invented a new medicine but have taken existing medicine and made it better."</span></p>
<p>Team member Boitumelo Semete says Rifanano will be targeted at government health departments in the developing world.</p>
<p>"TB is a poor man’s disease, which means it’s not a popular choice for development by commercially driven pharmaceutical companies," she says. "We are using local science and technology skills to make an existing treatment more effective and affordable for our people."</p>
<p><span>Nanotechnology is being used by scientists worldwide to improve the efficiency of treatment for a host of diseases. CSIR now plans to turn its attention to improving medications for a number of other diseases, including malaria and cancer.</span></p>
<p><span>The Bio Plan award ceremony was attended by Naledi Pandor, minister of science and technology, and Mamphela Ramphele, chair of the board for the new Technology Innovation Agency. The competition was organised in a joint collaboration between Emory University in the United States and South Africa’s Innovation Fund.</span></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/news/scientists-use-nanotech-to-upgrade-tb-drugs/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/news/scientists-use-nanotech-to-upgrade-tb-drugs/",null,true])
</script>
</div>

[DURBAN] South African scientists have used nanotechnology to enhance the absorption of tuberculosis (TB) drugs in the body so that fewer, smaller doses are needed.

Clinical trials for the antibiotic, Rifanano — a combination of the four main first-line TB drugs — are scheduled for 2012 and the drug should be available in government clinics in 2016, Hulda Swai, principal researcher in biomaterials research told SciDev.Net.

Swai and her team from the Council for Scientific and Industrial Research (CSIR) won ‘best science to business opportunity’ at the second SA Bio Plan Competition held during the recent Bio2Biz Conference in South Africa last week (20–23 September).

Rifanano needs to be taken just once a week for two months and there are no adverse reactions. Most TB antibiotics must be taken daily for up to six months and often cause debilitating side effects, such as nausea and fatigue.

The new drug is coated with nano-sized particles which are in turn coated with chemicals that make them stick to the intestine wall, enabling the drug to be far more easily absorbed.

"When the white blood cells see these particles they take them up because they look like foreign objects. But doing so they actually transport them throughout the body while releasing their cargo," says Swai.

"We have not invented a new medicine but have taken existing medicine and made it better."

Team member Boitumelo Semete says Rifanano will be targeted at government health departments in the developing world.

"TB is a poor man’s disease, which means it’s not a popular choice for development by commercially driven pharmaceutical companies," she says. "We are using local science and technology skills to make an existing treatment more effective and affordable for our people."

Nanotechnology is being used by scientists worldwide to improve the efficiency of treatment for a host of diseases. CSIR now plans to turn its attention to improving medications for a number of other diseases, including malaria and cancer.

The Bio Plan award ceremony was attended by Naledi Pandor, minister of science and technology, and Mamphela Ramphele, chair of the board for the new Technology Innovation Agency. The competition was organised in a joint collaboration between Emory University in the United States and South Africa’s Innovation Fund.